{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:25:55Z","timestamp":1790886355792,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Immunohistochemical markers shown to be useful in identifying\/confirming mesonephric\/mesonephric-like differentiation (MLD markers) include thyroid transcription factor (TTF1), GATA-binding protein 3 (GATA3), and cluster of differentiation 10 (CD10). Only a few studies have examined the expression levels of MLD markers in endometrial endometrioid carcinomas (EECs). This study aimed to analyze the frequency and pattern of MLD marker expression in low-grade EECs. We performed immunostaining for the detection of TTF1, GATA3, and CD10 expression in 50 low-grade EEC tissue samples and evaluated their staining proportion and intensity. Nine tumors (18.0%) expressed at least one MLD marker in varying proportions and intensities, and 2 of these tumors were positive for 2 MLD markers (TTF1\/GATA3 and GATA3\/CD10, respectively). Three (6.0%) tumors showed moderate-to-strong nuclear TTF1 immunoreactivity in \u22645% of the tumor cells. Five tumors (10.0%) had at least moderate nuclear GATA3 staining, and three of them displayed a staining proportion of \u226515%. Three tumors (6.0%) were focal (mean proportion, 15%) but strongly positive for CD10. Our findings indicate that a subset of EEC can express one or more MLD markers with varying staining proportions and intensities. Given that a diagnosis of uterine mesonephric-like adenocarcinoma should be established based on a combination of characteristic histologic features, unique immunophenotypes, and confirmed molecular findings, pathologists should not exclude EEC based only on the presence of focal immunoreactivity for MLD markers. Awareness of the atypical expression patterns of MLD markers in EEC helps pathologists avoid misdiagnosing EEC as a uterine mesonephric-like adenocarcinoma.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000976","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T17:38:54Z","timestamp":1691775534000},"page":"221-232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Yurimi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.21873\/anticanres.13573","article-title":"Displacement of vitamin D receptor is related to lower histological grade of endometrioid carcinoma","volume":"39","author":"An","year":"2019","journal-title":"Anticancer Res"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"526","DOI":"10.21873\/cgp.20338","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive analyses of clinicopathological, molecular, and prognostic characteristics with retrospective review of 237 endometrial carcinoma cases","volume":"19","author":"Kim","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/diagnostics11081450","article-title":"Mesonephric-like differentiation of endometrial endometrioid carcinoma: clinicopathological and molecular characteristics distinct from those of uterine mesonephric-like adenocarcinoma","volume":"11","author":"Park","year":"2021","journal-title":"Diagnostics"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/jcm10040698","article-title":"Mesonephric-like adenocarcinoma of the endometrium: diagnostic advances to spot this wolf in sheep\u2019s clothing. A review of the literature","volume":"10","author":"Deolet","year":"2021","journal-title":"J Clin Med"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/PAS.0000000000000471","article-title":"GATA3 Is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/modpathol.2015.103","article-title":"Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract","volume":"28","author":"Mirkovic","year":"2015","journal-title":"Mod Pathol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAS.0000000000000991","article-title":"Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body","volume":"43","author":"Na","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1097\/PAS.0000000000001142","article-title":"A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract","volume":"42","author":"Pors","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAS.0000000000001193","article-title":"A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium","volume":"43","author":"Kolin","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13000-019-0830-4","article-title":"Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Mullerian duct lineage: a case report","volume":"14","author":"Yano","year":"2019","journal-title":"Diagn Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PAS.0000000000001401","article-title":"Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior","volume":"44","author":"Euscher","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00432-019-03123-7","article-title":"Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma","volume":"146","author":"Horn","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/PAS.0000000000001612","article-title":"Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study","volume":"45","author":"Pors","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/diagnostics11112042","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive immunohistochemical analyses using markers for mesonephric, endometrioid and serous tumors","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/cancers14163911","article-title":"PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis","volume":"14","author":"Mamat Yusof","year":"2022","journal-title":"Cancers"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/ijerph192114451","article-title":"Mesonephric-like adenocarcinomas a rare tumor: the importance of diagnosis","volume":"19","author":"Restaino","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/PGP.0000000000000541","article-title":"GATA3 expression in common gynecologic carcinomas: a potential pitfall","volume":"38","author":"Terzic","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4132\/jptm.2019.10.24","article-title":"Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast","volume":"54","author":"Jang","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/diagnostics10080580","article-title":"Primary retroperitoneal mucinous carcinoma with carcinosarcomatous mural nodules: a case report with emphasis on its histological features and immunophenotype","volume":"10","author":"Park","year":"2020","journal-title":"Diagnostics"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.21873\/anticanres.15053","article-title":"Dedifferentiated mesonephric-like adenocarcinoma of the uterine corpus","volume":"41","author":"Choi","year":"2021","journal-title":"Anticancer Res"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.21873\/invivo.12499","article-title":"Clinicopathological characteristics of gastric-type endocervical adenocarcinoma misdiagnosed as an endometrial, ovarian or extragenital malignancy, or mistyped as usual-type endocervical adenocarcinoma","volume":"35","author":"Koh","year":"2021","journal-title":"In Vivo"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/diagnostics11040717","article-title":"Serous carcinoma of the endometrium with mesonephric-like differentiation initially misdiagnosed as uterine mesonephric-like adenocarcinoma: a case report with emphasis on the immunostaining and the identification of splice site TP53 mutation","volume":"11","author":"Choi","year":"2021","journal-title":"Diagnostics"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2022.06.027","article-title":"Microcystic, elongated, and fragmented (MELF) pattern of invasion: molecular features and prognostic significance in the PORTEC-1 and -2 trials","volume":"166","author":"van den Heerik","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1159\/000510441","article-title":"Usual-type endocervical adenocarcinoma with a microcystic, elongated, and fragmented pattern of stromal invasion: a case report with emphasis on Ki-67 immunostaining and targeted sequencing results","volume":"13","author":"Choi","year":"2020","journal-title":"Case Rep Oncol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejso.2020.06.041","article-title":"Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion","volume":"47","author":"Santoro","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.humpath.2017.05.026","article-title":"Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance","volume":"70","author":"Espinosa","year":"2017","journal-title":"Hum Pathol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/00313020903041135","article-title":"MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion","volume":"41","author":"Stewart","year":"2009","journal-title":"Pathology"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/modpathol.2011.208","article-title":"Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing","volume":"25","author":"Djordjevic","year":"2012","journal-title":"Mod Pathol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/PAS.0000000000001873","article-title":"Mesonephric-like endometrial carcinoma: results from immunohistochemical screening of 300 endometrial carcinomas and carcinosarcomas for this often overlooked and potentially aggressive entity","volume":"46","author":"Mills","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/PAS.0b013e3181131e21","article-title":"Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas","volume":"31","author":"Siami","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pathol.2019.02.003","article-title":"Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas","volume":"51","author":"Moritz","year":"2019","journal-title":"Pathology"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PAS.0000000000000958","article-title":"Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract","volume":"42","author":"Mirkovic","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2559.2003.01684.x","article-title":"CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma","volume":"43","author":"McCluggage","year":"2003","journal-title":"Histopathology"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/modpathol.2012.64","article-title":"Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development","volume":"25","author":"Sullivan","year":"2012","journal-title":"Mod Pathol"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1309\/CADCVWHR2QF6JMVN","article-title":"Cytoplasmic immunoreactivity of thyroid transcription factor-1 (clone 8G7G3\/1) in hepatocytes: true positivity or cross-reaction?","volume":"128","author":"Gu","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1309\/8BM44NK626997DJJ","article-title":"Cytoplasmic immunoreactivity for thyroid transcription factor-1 in hepatocellular carcinoma: a comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique","volume":"121","author":"Pan","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R40-20250802","first-page":"1","article-title":"GATA3 expression in human tumors: a tissue microarray study on 16,557 tumors","author":"Reiswich","year":"2023","journal-title":"Pathobiology"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP5UAFMSA9ZQBZ","article-title":"Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas","volume":"138","author":"Liu","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R42-20250802","first-page":"S20","article-title":"Expression of GATA3 in epithelial tumors","volume":"70","author":"Asif","year":"2020","journal-title":"Pak Armed Forces Med J"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:01:27Z","timestamp":1754161287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000976","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}